Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 08 January 2013 | By Alexander Gaffney, RAC,
The US Food and Drug's Administration's (FDA) Unified Agenda may have been released late last year, but it's not the only US regulatory agency with the potential to affect the medical device and pharmaceutical industries.
Several regulations proposed by the Drug Enforcement Administration (DEA), a division of the US Department of Justice, hold the potential to affect members of industry, and in particular the pharmaceutical industry.
One such proposed rule, Disposal of Controlled Substances, proposes to require a system in which manufacturers and users would need to secure leftover or otherwise unused controlled substances (any scheduled substance under the Controlled Substances Act, or CSA) for proper disposal.
"The proposed rule would also reorganize and consolidate existing regulations on disposal, including the role of reverse distributors, and propose a comprehensive regulatory framework for the collection and destruction of controlled substances consistent with the CSA," DEA wrote. The regulation is required under the terms of the Secure and Responsible Drug Disposal Act of 2010, and DEA has already sought opinions from industry in the form of a January 2009 Federal Register notice in which it called for "options for the safe and responsible disposal of dispensed controlled substance."
At issue could be who pays for the system-end users, the facilities that dispense the drugs, or the drug manufacturers-and what will it eventually entail? DEA's notice holds few details at this time. The rule is still in the proposed rule stage, and does not have any legal deadlines, meaning it could be well beyond 2013 before the final rule is seen or enacted.
DEA is also looking to implement several regulations aimed at preventing the proliferation of methamphetamines.
One such regulation, Implementation of the Combat Methamphetamine Epidemic Act (MEA) of 2005; notice of transfers following importation or exportation, would apply to importers, exporters and persons handling List I and List II chemicals. Those chemicals are those used in the manufacture of controlled substances under the CSA, and DEA has been looking to control their supply chain more carefully to prevent the types of diversions that can fuel the unregulated and illicit manufacture of meth. Under the proposed rule, the identified entities would have to provide DEA with information about to whom they will transfer the substance, as well as the amount to be transferred and a declaration that the transfer has occurred.
Final action on that rule is expected on or about 1 August 2012. A similar regulation, Self-Certification and Employee Training of Mail-Order Distributors of Scheduled Listed Chemical Products, would apply to mail-order distributors of scheduled listed chemical products, which would need to self-certify to DEA in order to sell the substances, which could in turn affect the sales of the products (and in particular cold remedies).
Yet another proposed regulation, Retail Sales of Scheduled Listed Products; Chemical; Self-Certification of Regulated Sellers of Scheduled Listed Chemical Products, would create 30-day and daily sales limits, require scheduled products to be sold from behind the counter of a retail operation, would mandate that the identification of purchasers be logged, and that all employees handling scheduled goods be trained and certified.
A final proposed regulation, set to be unveiled in June 2013, would revise current regulations regarding anabolic steroid products. DEA explained that the products are currently exempted under the law from the requirements of 21 USC 801-904. Its regulations, however, exempt it from 21 USC 951-971.
"DEA would revise its regulations to reflect the authority provided by Congress in the CSA and would review ways that the exemption process may be updated and streamlined," it wrote. "As such, DEA would repeal any portion of its regulations that allow the exemption of chemical preparations and anabolic steroid products from application of sections 1002, 1003, and 1004 of the CSA (21 U.S.C. 952-954) and its implementing regulations."
Tags: MEA, Methamphetamine, Controlled Substances Act, CSA, disposal, Supply Chain, DEA, pharmaceutical, industry, drug
Regulatory Focus newsletters
All the biggest regulatory news and happenings.